Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Tilray Brands, Inc. TLRY

Alternate Symbol(s):  T.TLRY

Tilray Brands, Inc. is a global cannabis-lifestyle and consumer packaged goods company. The Company operates through four segments: Cannabis business, Distribution business, Beverage alcohol business and Wellness business. The Cannabis business segment is engaged in the production, distribution, sale, co-manufacturing, and advisory services of both medical and adult-use cannabis. The... see more

NDAQ:TLRY - Post Discussion

Tilray Brands, Inc. > Tilray Brands 1st Quarter
View:
Post by DaveInCalgary on Oct 04, 2023 11:14am

Tilray Brands 1st Quarter

Tilray Throws Investors a Bone with Q1 Beat

Adam Jackson, Oct 4, 2023


Tilray Brands Inc. (Nasdaq: TLRY) (TSX: TLRY) posted its first-quarter 2024 financial results ending Aug. 31, showing a mixed bag, with gains in revenue amid shrinking cannabis margins. However, the company still beat analyst predictions.

The Canadian producer, which has been on an M&A binge lately, reported 15% revenue growth to $177 million from the prior year’s $153 million. This beat Yahoo analysts’ average of $174 million.

“Since the beginning of our (fiscal year), we have closed on three transactions: HEXO Corp. in June, Truss Beverage Co. in August, and the acquisition of eight beer and beverage brands from Anheuser-Busch,” CEO Irwin Simon said in a statement Wednesday.

“We have strategically diversified our company globally over the past several years and, as a result, Tilray is now ideally positioned to capture a wide range of opportunities across multiple industries.”

Tilray’s cannabis segment revenue rose by 20% to $70 million, up from $59 million in the same period last year. However, the division’s gross margin registered at 28%, a considerable slump from the 51% reported the previous year. The adjusted gross margin for the segment echoed a similar sentiment, falling to 35% from last year’s 51%.

Factors such as a wholesale deal meant “for inventory optimization,” which generated an additional $3.1 million in cash, influenced this margin shift. The impact of the HEXO advisory fee revenue, included in the prior year, also contributed.

On the opposite end, company’s beverage alcohol division continued its upward trend, with revenues spiking by 17% to reach $24 million, compared to the prior year’s $21 million. The alcohol segment also showcased a marked rise in gross margin, climbing to 53% from the previous year’s 47%.

The company’s net loss was $56 million for the quarter, an improvement against the previous year’s $66 million loss. Adjusted EBITDA was $11.4 million in the first quarter versus $13.5 million in the prior year quarter, mostly as a result of revenue generated from fees paid for advisory services related to the HEXO acquisition.

Tilray anticipates an adjusted EBITDA between $68 million to $78 million for the fiscal year ending May 31, 2024, with expectations of generating a positive adjusted free cash flow.

https://www.greenmarketreport.com/tilray-throws-investors-a-bone-with-q1-beat/

Comment by quinlash on Oct 04, 2023 11:25am
The great thing about TLRY is the alchol product offering.  With or without substantial progress with US Cannabis Legalization (which I believe is a WHEN, not an IF) the sales numbers coming in from alchol will keep growing this company and the margins on those products exceed my minimum expectation for product-based sales.   On the Cannabis side, I like that sales grew, I expected ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities